<DOC>
	<DOCNO>NCT02024841</DOCNO>
	<brief_summary>Phase I study maximum tolerate dose ( MTD ) recommend dose ( RD ) intraperitoneal docetaxel combine intravenous cisplatin oral TS-ONE gastric cancer patient peritoneal carcinomatosis</brief_summary>
	<brief_title>Intraperitoneal Docetaxel With Cisplatin TS-ONE Gastric Cancer With Peritoneal Carcinomatosis</brief_title>
	<detailed_description>Peritoneal carcinomatosis ( PC ) common advanced gastric cancer , carry poor prognosis ; median survival time 3 6 month . Gastric cancer PC consider incurable patient subject non-surgical treatment , mainly chemotherapy . Currently , establish standard treatment patient . Multidisciplinary approach treatment gastric cancer include chemotherapy , radiotherapy surgery develop survival benefit demonstrate adjuvant setting . Novel chemotherapeutic agent : taxanes ( paclitaxel docetaxel ) , irinotecan , oxaliplatin , fluoropyrimidine ( TS-ONE capecitabine ) show activity gastric cancer . Various combination chemotherapy regimens unresectable metastatic gastric cancer practise different part world . Epirubicin , cisplatin 5-fluorouracil ( ECF ) use Europe , TS-ONE cisplatin commonly use Asian country Japan Korea . The median survival time ( MST ) regimens 8.9 13 month , respectively . Use docetaxel , cisplatin 5-fluorouracil ( DCF ) propose V325 study , MST 9.2 month toxicity ( grade 3-4 neutropenia ) report significantly high DCF group compare CF group . However , trial study specific efficacy regimens PC . Systemic chemotherapy consider less effective PC due existence blood-peritoneal barrier ( BPB ) . The barrier inhibits movement drug systemic circulation peritoneal cavity . Intraperitoneal ( IP ) chemotherapy advantage maintain high drug concentration peritoneal cavity , reduce systemic toxicity . Paclitaxel docetaxel show high peritoneal concentration animal study consider ideal drug IP administration . Neoadjuvant intraperitoneal/systemic chemotherapy ( NIPS ) new bidirectional induction chemotherapy treatment PC gastric cancer . The aim NIPS induce reduction PC volume . Bidirectional mean NIPS could attack PC peritoneal cavity subperitoneal blood vessel . Patients good response NIPS may undergo subsequent gastrectomy . The use TS-ONE IP taxane ( paclitaxel/docetaxel ) study phase I II trial . Ischigami et al . report 1-year survival rate 78 % overall response rate 56 % use weekly intravenous IP paclitaxel combine TS-ONE . Fujiwara et al . report 78 % patient negative peritoneal cytology NIPS 16 18 patient ( 88.9 % ) underwent subsequent gastrectomy , MST 24.6 month . No treatment-related mortality report . Systemic DCF associate significant toxicity , yet superior CF alone term survival ( 9.2 month vs. 8.6 month , p &lt; 0.02 ) . Grade III/IV neutropenia report 82 % . It postulate switch intravenous docetaxel IP docetaxel may improve efficacy PC reduce systemic toxicity . TS-ONE contains tegafur , 5-chloro-2,4-dihydroxypyridine ( CDHP ) potassium oxonate ( Oxo ) . Dihydropyrimidine dehydrogenase ( DPD ) , find liver , rapidly degrade 5-FU . The presence CDHP , specific inhibitor DPD , allow high intraperitoneal drug concentration oral administration TS-ONE demonstrate experimental model . Therefore propose modification DCF regimen use IP docetaxel , intravenous cisplatin oral TS-ONE treatment gastric cancer patient PC . We aim study maximum tolerate dose ( MTD ) recommend dose ( RD ) IP docetaxel use fix dos cisplatin TS-ONE . Data treatment efficacy also record . By far study IP chemotherapy Hong Kong .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age≥18 Histologic confirmation gastric adenocarcinoma Positive peritoneal cytology histological proven PC Absence distant metastasis except peritoneum lymph node ( ) Adequate bone marrow organ function define : Leucocyte ≥3.00 x 109/L Absolute neutrophil count ≥ 1.50 x 109/L Platelet ≥ 100 x 109/L Total bilirubin ≤2 x ULN AST/ALT ≤2.5 x ULN Creatinine clearance ≥60ml/min Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Subjects childbearing potential must agree contraception screen 6 month completion treatment Provision write informed consent Any prior anticancer therapy gastric cancer Previous exposure taxane , fluoropyrimidine platinum chemotherapy Previous radiotherapy abdomen pelvic region Known hypersensitivity study medication Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Any prior synchronous malignancy , except , Malignancy treat curative intent evidence disease ≥5 year prior enrollment consider low risk recurrence treat physician Adequately treated nonmelanoma skin cancer lentigo maligna without evidence disease Subject pregnant breast feed Any serious concomitant illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Peritoneal carcinomatosis</keyword>
	<keyword>Intraperitoneal docetaxel</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>TS-ONE</keyword>
</DOC>